Omalizumab substantially improves dermatology‐related quality of life in patients with chronic spontaneous urticariaA.Y. Finlay, Marcus Maurer, S Khalil et al.|Journal of the European Academy of Dermatology and Venereology|2017Cited by 50
Correlations Between Changes in the Urticaria Activity Score (UAS7) and the Dermatology Life Quality Index (DLQI) from Baseline to 28 or 40 Weeks: Comparisons of Trajectories of Change in Patients with Chronic Spontaneous/Idiopathic Urticaria (CSU/CIU)Donald E. Stull, Ari Gnanasakthy, Doreen McBride et al.|Value in Health|2013Cited by 3
Estimating Utility Data for Patient Symptom Severity in Chronic Spontaneous UrticariaEmma Hawe, M.M. Balp, Doreen McBride et al.|Value in Health|2014Cited by 1